SLC11A2 and chronic myelogenous leukemia, BCR-ABL1 positive: In our clinically independent cohort study, we also observed a significant decrease in ACSL6, SLC11A2, HMOX1, and SLC38A1 expression in CML samples while AKR1C3 did not show a significant difference due to small sample size issues (Figure 4I).